Pheon Therapeutics is an Antibody‑Drug Conjugate (ADC) specialist based in Harpenden, near London, developing next‑generation ADCs targeting hard‑to‑treat cancers. Its pipeline employs novel targets and novel linker‑payload combinations, with a lead program described as a first‑in‑class ADC against a target highly overexpressed across multiple solid tumor types. The company is led by CEO Cyrus Mozayeni, MD. Pheon expects to start its first Phase 1 clinical trial in 2024 and rapidly advance toward dose‑expansion cohorts. It closed a $120M Series B to fund clinical proof‑of‑concept work and to expand its suite of in‑house technology platforms to generate optimized ADC constructs. Pheon Therapeutics, based in London, is developing a pipeline of antibody–drug conjugates (ADCs) as monotherapies against novel targets and with novel payloads. The company's lead program is described as a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon highlights ADCs' potential to treat solid tumors and liquid cancers that have not responded to other treatments. It intends to use the funds to advance its lead ADC program to clinical proof-of-concept and to establish a broader pipeline of novel ADCs. The company is led by CEO Bertrand Damour and CSO Leigh Zawel, and its board includes partners from Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.

Total raised

$188M

Funding rounds

2

Latest round

Series B

Latest activity

May 2024